Association between type 2 inflammatory diseases and neurodevelopmental disorders in low-birth-weight children and adolescents.

Hengye Huang, Kelvin Pengyuan Zhang, Karol Kexin Sun, Guangjun Yu
Author Information
  1. Hengye Huang: School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  2. Kelvin Pengyuan Zhang: School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  3. Karol Kexin Sun: School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  4. Guangjun Yu: Shanghai Engineering Research Center for Big Data in Pediatric Precision Medicine, Center for Biomedical Informatics, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Abstract

Background: Evidence of the association of certain neurodevelopmental disorder with specific type 2 inflammatory (T2) disease has been found. However, the association of various neurodevelopmental disorders with T2 diseases as a whole remains unclear in low-birth-weight (LBW) infants.
Objective: To evaluate the association of type 2 inflammatory (T2) diseases with intellectual disability (ID), autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), and learning disability (LD) in LBW children and adolescents.
Methods: The study sample was derived from 2005 to 2018 National Health Interview Survey sample child files. LBW children and adolescents aged 3-17 were included. History of T2 diseases (including asthma and atopic dermatitis) and four neurodevelopmental disorders were reported by adults in families. The relationship between T2 diseases and the risk of four neurodevelopmental disorders was investigated through multiple-weighted logistic regression. Age, sex, race/ethnicity, region, highest education in family and ratio of family income to the poverty threshold were adjusted as covariates for model estimation. Subgroup analyses were conducted by age stratification (3-11 and 12-17 years), sex (male and female), and race (white and non-white).
Results: 11,260 LBW children aged 3-17 years [mean age (SE), 9.73 (0.05) years] were included, in which 3,191 children had T2 diseases. History of T2 diseases was associated with an increased risk of neurodevelopmental disorders, with an OR of 1.35 (95% CI, 0.99-1.84) for ID, 1.47 (95% CI, 1.05-2.05) for ASD, 1.81 (95% CI, 1.51-2.16) for ADHD, and 1.74 (95% CI, 1.49-2.04) for LD following the adjustment of all the covariates. The correlations between T2 disorders and each of the four neurodevelopmental disorders were significantly different by sex and race (all for interaction < 0.001), and no differences were found in age stratification (all for interaction > 0.05).
Conclusion: In a nationally representative sample of children, we found a significant association of T2 diseases with ASD, ADHD, and LD, even after adjusting for demographic baseline. We also found that the association of T2 disease with neurodevelopmental disorders differed between sex and race. Further investigation is needed to evaluate causal relationships and elucidate their potential mechanisms.

Keywords

References

  1. Mol Psychiatry. 2023 Jan;28(1):108-117 [PMID: 36284159]
  2. Front Immunol. 2018 Aug 27;9:1931 [PMID: 30210492]
  3. J Asthma Allergy. 2021 Sep 29;14:1173-1183 [PMID: 34616157]
  4. Heart Lung Circ. 2014 Jun;23(6):511-9 [PMID: 24582482]
  5. J Neurodev Disord. 2021 Sep 21;13(1):41 [PMID: 34548007]
  6. Lancet Infect Dis. 2016 Aug;16(8):952-61 [PMID: 27052469]
  7. Autism Res. 2022 Apr;15(4):740-750 [PMID: 35112480]
  8. Pediatr Allergy Immunol. 2020 Feb;31 Suppl 24:16-18 [PMID: 32017219]
  9. Sci Rep. 2022 Mar 1;12(1):3377 [PMID: 35232975]
  10. Front Neuroendocrinol. 2012 Aug;33(3):267-86 [PMID: 22982535]
  11. J Matern Fetal Neonatal Med. 2011 Jan;24(1):25-31 [PMID: 20569168]
  12. J Pediatr. 2021 Jan;228:183-189.e2 [PMID: 33035572]
  13. Fam Community Health. 2021 Jan/Mar;44(1):52-58 [PMID: 33214410]
  14. J Pediatr (Rio J). 2015 Jul-Aug;91(4):326-32 [PMID: 25913048]
  15. Matern Child Health J. 2015 Aug;19(8):1687-97 [PMID: 25701197]
  16. Neural Dev. 2018 May 1;13(1):7 [PMID: 29712572]
  17. Int Rev Immunol. 2002 Nov-Dec;21(6):471-95 [PMID: 12650238]
  18. Neuroimmunomodulation. 2015;22(1-2):6-19 [PMID: 25227402]
  19. Dermatology. 2024;240(1):13-25 [PMID: 37939694]
  20. Pediatr Allergy Immunol. 2016 Dec;27(8):847-853 [PMID: 27591739]
  21. Front Cell Dev Biol. 2021 May 11;9:661486 [PMID: 34046407]
  22. Lancet Psychiatry. 2018 Sep;5(9):717-726 [PMID: 30054261]
  23. Chest. 2018 May;153(5):1279-1280 [PMID: 29731041]
  24. Clin Perinatol. 2018 Sep;45(3):409-420 [PMID: 30144846]
  25. Int J Epidemiol. 2011 Jun;40(3):647-61 [PMID: 21324938]
  26. J Am Acad Dermatol. 2022 Apr;86(4):758-765 [PMID: 34756933]
  27. Dev Cogn Neurosci. 2022 Oct;57:101143 [PMID: 35933922]
  28. J Allergy Clin Immunol. 2021 Dec;148(6):1430-1441 [PMID: 34655640]
  29. Pediatr Dermatol. 2021 Sep;38(5):1032-1039 [PMID: 34338364]
  30. Res Dev Disabil. 2011 Mar-Apr;32(2):419-36 [PMID: 21236634]
  31. Cell Rep. 2022 Aug 2;40(5):111152 [PMID: 35926465]
  32. Brain Behav Immun. 2022 Feb;100:121-133 [PMID: 34808292]
  33. Neurosci Biobehav Rev. 2020 Oct;117:26-64 [PMID: 28757456]
  34. Arch Dermatol Res. 2022 Apr;314(3):267-274 [PMID: 33817750]
  35. Lancet. 2017 Dec 17;388(10063):3027-3035 [PMID: 27839855]
  36. Neurosci Biobehav Rev. 2022 Apr;135:104577 [PMID: 35167846]
  37. Epidemiology. 2000 Mar;11(2):185-8 [PMID: 11021618]
  38. Front Neurosci. 2013 May 21;7:79 [PMID: 23734091]
  39. Lancet. 2020 Aug 1;396(10247):345-360 [PMID: 32738956]
  40. Ann Nutr Metab. 2015;66 Suppl 1:8-16 [PMID: 25925336]
  41. Ann Allergy Asthma Immunol. 2021 Jun;126(6):661-665 [PMID: 33189871]
  42. Ital J Dermatol Venerol. 2022 Feb;157(1):1-12 [PMID: 34929995]
  43. Autism Res. 2019 Jan;12(1):123-135 [PMID: 30095240]
  44. Clin Exp Allergy. 2021 Feb;51(2):228-252 [PMID: 32997856]
  45. Nat Rev Immunol. 2021 Jul;21(7):454-468 [PMID: 33479477]
  46. Dev Neurosci. 2014;36(2):119-31 [PMID: 24642725]
  47. Curr Top Behav Neurosci. 2023;62:165-206 [PMID: 35435643]
  48. Nutrients. 2022 Jan 21;14(3): [PMID: 35276830]
  49. Lancet. 2012 Feb 4;379(9814):445-52 [PMID: 22244654]
  50. Chest. 2017 Jun;151(6):1406-1407 [PMID: 28599940]
  51. Allergy. 2020 Jul;75(7):1582-1605 [PMID: 32319104]
  52. Exp Neurol. 2018 Jan;299(Pt A):241-251 [PMID: 28698032]
  53. J Am Acad Dermatol. 2021 Feb;84(2):471-478 [PMID: 32112994]
  54. Eur Child Adolesc Psychiatry. 2009 Sep;18(9):543-53 [PMID: 19294447]
  55. Neurosci Biobehav Rev. 2017 Mar;74(Pt A):139-148 [PMID: 28111269]
  56. Prog Neurobiol. 2022 Jul;214:102282 [PMID: 35533811]
  57. J Allergy Clin Immunol Pract. 2020 Sep;8(8):2808-2810 [PMID: 32348912]
  58. Trends Neurosci. 2019 May;42(5):337-348 [PMID: 30890276]

Word Cloud

Created with Highcharts 10.0.0T2neurodevelopmentaldisordersdiseases1childrenassociationdisorderfoundLBWdisabilitysex095%CItype2inflammatorylow-birth-weightASDADHDLDadolescentssamplefouragerace05diseaseevaluateintellectualIDautismspectrumattentiondeficithyperactivitylearningaged3-17includedHistoryasthmaatopicriskfamilycovariatesstratificationyearsinteractionBackground:EvidencecertainspecificHowevervariouswholeremainsunclearinfantsObjective:Methods:studyderived20052018NationalHealthInterviewSurveychildfilesincludingdermatitisreportedadultsfamiliesrelationshipinvestigatedmultiple-weightedlogisticregressionAgerace/ethnicityregionhighesteducationratioincomepovertythresholdadjustedmodelestimationSubgroupanalysesconducted3-1112-17malefemalewhitenon-whiteResults:11260[meanSE973years]3191associatedincreasedOR3599-1844705-28151-2167449-204followingadjustmentcorrelationssignificantlydifferent<001differences>Conclusion:nationallyrepresentativesignificantevenadjustingdemographicbaselinealsodifferedinvestigationneededcausalrelationshipselucidatepotentialmechanismsAssociation

Similar Articles

Cited By